Eléments de l'association
|  |
List of bibliographic references
Number of relevant bibliographic references: 5.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 002993 | Christopher Arthur [Australie] ; Jaroslav Cermak [République tchèque] ; Jacques Delaunay [France] ; Ji Mayer [République tchèque] ; Grzegorz Mazur [Pologne] ; Xavier Thomas [France] ; Agnieszka Wierzbowska [Pologne] ; Mark M. Jones [États-Unis] ; Erhan Berrak [États-Unis] ; Hagop Kantarjian [États-Unis] | Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia |
| 002F56 | Tapan M. Kadia [États-Unis] ; Xavier G. Thomas [France] ; Anna Dmoszynska [Pologne] ; Agnieszka Wierzbowska [Pologne] ; Mark Minden [Canada] ; Christopher Arthur [Australie] ; Jacques Delaunay [France] ; Farhad Ravandi [États-Unis] ; Hagop Kantarjian [États-Unis] | Decitabine Improves Outcomes in Older Patients with Acute Myeloid Leukemia (AML) and Higher Blast Counts |
| 003699 | Ji Mayer [République tchèque] ; Christopher Arthur [Australie] ; Jacques Delaunay [France] ; Grzegorz Mazur [Pologne] ; Xavier G. Thomas [France] ; Agnieszka Wierzbowska [Pologne] ; Farhad Ravandi [États-Unis] ; Erhan Berrak [États-Unis] ; Mark Jones [États-Unis] ; Yuhan Li [États-Unis] ; Hagop M. Kantarjian [États-Unis] | Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics |
| 003C42 | Xavier G. Thomas [France] ; Christopher Arthur [Australie] ; Jacques Delaunay [France] ; Mark Jones [États-Unis] ; Erhan Berrak [États-Unis] ; Hagop M. Kantarjian [États-Unis] | A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. |
| 005A68 | Hagop M. Kantarjian [États-Unis] ; Xavier G. Thomas [France] ; Anna Dmoszynska [Pologne] ; Agnieszka Wierzbowska [Pologne] ; Grzegorz Mazur [Pologne] ; Jiri Mayer [République tchèque] ; Jyh-Pyng Gau [Taïwan] ; Wen-Chien Chou [Taïwan] ; Rena Buckstein [Canada] ; Jaroslav Cermak [République tchèque] ; Ching-Yuan Kuo [Taïwan] ; Albert Oriol [Espagne] ; Farhad Ravandi [États-Unis] ; Stefan Faderl [États-Unis] ; Jacques Delaunay [France, Australie] ; Daniel Lysak [République tchèque] ; Mark Minden ; Christopher Arthur | Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
| This area was generated with Dilib version V0.6.33. |  |